Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 3 | 2022 | 105 | 1.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 86 | 0.830 |
Why?
|
| Cholangiocarcinoma | 3 | 2023 | 66 | 0.650 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 79 | 0.640 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 266 | 0.610 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 736 | 0.570 |
Why?
|
| Adenocarcinoma | 5 | 2023 | 1169 | 0.500 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 386 | 0.490 |
Why?
|
| Thyroid Neoplasms | 3 | 2023 | 408 | 0.450 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 645 | 0.260 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 138 | 0.230 |
Why?
|
| Radioisotopes | 1 | 2022 | 45 | 0.220 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 13 | 0.210 |
Why?
|
| Transplants | 1 | 2022 | 40 | 0.210 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 322 | 0.190 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 238 | 0.190 |
Why?
|
| Octreotide | 1 | 2020 | 16 | 0.190 |
Why?
|
| Coordination Complexes | 1 | 2020 | 19 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2020 | 27 | 0.180 |
Why?
|
| ras Proteins | 1 | 2020 | 128 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 73 | 0.180 |
Why?
|
| Intestinal Neoplasms | 1 | 2020 | 56 | 0.180 |
Why?
|
| Yttrium Radioisotopes | 3 | 2023 | 46 | 0.170 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 70 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2438 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 177 | 0.170 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 185 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 645 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2021 | 272 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2022 | 4212 | 0.150 |
Why?
|
| Transcriptome | 1 | 2020 | 580 | 0.140 |
Why?
|
| Humans | 16 | 2023 | 86656 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1197 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2023 | 7982 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 931 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1380 | 0.130 |
Why?
|
| Quality of Life | 1 | 2022 | 1587 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1271 | 0.120 |
Why?
|
| Microspheres | 2 | 2023 | 101 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 1686 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2023 | 8476 | 0.100 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 73 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 329 | 0.080 |
Why?
|
| Neoplasms | 1 | 2021 | 2898 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6511 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 1938 | 0.070 |
Why?
|
| Aged | 4 | 2021 | 18407 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 70 | 0.060 |
Why?
|
| Necrosis | 1 | 2023 | 204 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 134 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 96 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 58 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 48 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 51 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 72 | 0.050 |
Why?
|
| Middle Aged | 4 | 2021 | 25027 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 162 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 411 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2021 | 68 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 612 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 56 | 0.050 |
Why?
|
| Mutation | 2 | 2022 | 3977 | 0.050 |
Why?
|
| DNA Repair | 1 | 2022 | 356 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 218 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1204 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 429 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 132 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 861 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 915 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 556 | 0.040 |
Why?
|
| Male | 4 | 2021 | 40995 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 25648 | 0.040 |
Why?
|
| Female | 4 | 2021 | 44566 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 631 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 3048 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 1864 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1853 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1387 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2360 | 0.020 |
Why?
|